Novartis launches single infusion for Paget's disease

Novartis has launched Aclasta, an intravenous formulation of the bisphosphonate zoledronic acid indicated for the treatment of Paget's disease of the bone.

The recommended dose of Aclasta is a single intravenous infusion of 5mg in 100ml aqueous solution administered via a vented infusion line over at least 15 minutes.

Clinical trials have shown that a single 5mg infusion of Aclasta achieves a more sustained biochemical remission, defined as either normalisation of serum alkaline phosphatase or a reduction of at least 75% from baseline in total serum alkaline phosphatase at the end of 6 months, than oral risedronate 30mg daily for 60 days.

Furthermore, prolonged observation of patients who responded to treatment has shown that at a mean of 630 days beyond the six-month initial trial, 98% of patients maintained a therapeutic response versus 50% of those who received risedronate, and the rate of relapse was also significantly lower (2% vs 43%).

Aclasta is presented as a 5mg per 100ml solution at a basic NHS price of £283.74 per 100ml.

Further information: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR. Tel: (01276) 692255.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases